23.41 USD
-0.02 (-0.09%)
23.6 USD
+0.19 (+0.81%)
We assign a fundamental rating of 8 out of 10 to CPRX. CPRX was compared to 533 industry peers in the Biotechnology industry. CPRX gets an excellent profitability rating and is at the same time showing great financial health properties. CPRX has both an excellent growth and valuation score. This means it is growing and it is still cheap. This is a rare combination! This makes CPRX very considerable for value and growth and quality investing!
1. Profitability
1.1 Basic Checks
In the past year CPRX was profitable.
In the past year CPRX had a positive cash flow from operations.
In the past 5 years CPRX has always been profitable.
In the past 5 years CPRX always reported a positive cash flow from operatings.
1.2 Ratios
The Return On Assets of CPRX (20.69%) is better than 97.00% of its industry peers.
CPRX's Return On Equity of 23.65% is amongst the best of the industry. CPRX outperforms 96.62% of its industry peers.
The Return On Invested Capital of CPRX (21.23%) is better than 97.75% of its industry peers.
CPRX had an Average Return On Invested Capital over the past 3 years of 20.37%. This is in line with the industry average of 18.83%.
The 3 year average ROIC (20.37%) for CPRX is below the current ROIC(21.23%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.69% | ||
| ROE | 23.65% | ||
| ROIC | 21.23% |
ROA(3y)18.85%
ROA(5y)22.43%
ROE(3y)22.87%
ROE(5y)26.38%
ROIC(3y)20.37%
ROIC(5y)19.67%
1.3 Margins
CPRX has a Profit Margin of 37.64%. This is amongst the best in the industry. CPRX outperforms 96.81% of its industry peers.
In the last couple of years the Profit Margin of CPRX has remained more or less at the same level.
Looking at the Operating Margin, with a value of 44.78%, CPRX belongs to the top of the industry, outperforming 99.44% of the companies in the same industry.
In the last couple of years the Operating Margin of CPRX has grown nicely.
With an excellent Gross Margin value of 85.68%, CPRX belongs to the best of the industry, outperforming 87.80% of the companies in the same industry.
CPRX's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 44.78% | ||
| PM (TTM) | 37.64% | ||
| GM | 85.68% |
OM growth 3Y2.16%
OM growth 5Y5%
PM growth 3Y5.91%
PM growth 5Y1.34%
GM growth 3Y0.61%
GM growth 5Y0.11%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so CPRX is creating value.
Compared to 1 year ago, CPRX has more shares outstanding
The number of shares outstanding for CPRX has been increased compared to 5 years ago.
CPRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
CPRX has an Altman-Z score of 15.94. This indicates that CPRX is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 15.94, CPRX belongs to the best of the industry, outperforming 87.80% of the companies in the same industry.
CPRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 15.94 |
ROIC/WACC2.46
WACC8.64%
2.3 Liquidity
CPRX has a Current Ratio of 6.62. This indicates that CPRX is financially healthy and has no problem in meeting its short term obligations.
CPRX's Current ratio of 6.62 is fine compared to the rest of the industry. CPRX outperforms 68.67% of its industry peers.
A Quick Ratio of 6.40 indicates that CPRX has no problem at all paying its short term obligations.
The Quick ratio of CPRX (6.40) is better than 67.35% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.62 | ||
| Quick Ratio | 6.4 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 45.76% over the past year.
Measured over the past years, CPRX shows a very strong growth in Earnings Per Share. The EPS has been growing by 34.29% on average per year.
The Revenue has grown by 25.56% in the past year. This is a very strong growth!
The Revenue has been growing by 36.89% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)45.76%
EPS 3Y52.41%
EPS 5Y34.29%
EPS Q2Q%20%
Revenue 1Y (TTM)25.56%
Revenue growth 3Y51.72%
Revenue growth 5Y36.89%
Sales Q2Q%15.31%
3.2 Future
The Earnings Per Share is expected to grow by 26.80% on average over the next years. This is a very strong growth
Based on estimates for the next years, CPRX will show a quite strong growth in Revenue. The Revenue will grow by 11.21% on average per year.
EPS Next Y13.52%
EPS Next 2Y14.64%
EPS Next 3Y10.93%
EPS Next 5Y26.8%
Revenue Next Year16.1%
Revenue Next 2Y12.2%
Revenue Next 3Y11.06%
Revenue Next 5Y11.21%
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 13.61, which indicates a correct valuation of CPRX.
CPRX's Price/Earnings ratio is rather cheap when compared to the industry. CPRX is cheaper than 96.06% of the companies in the same industry.
CPRX is valuated rather cheaply when we compare the Price/Earnings ratio to 26.15, which is the current average of the S&P500 Index.
With a Price/Forward Earnings ratio of 13.60, CPRX is valued correctly.
CPRX's Price/Forward Earnings ratio is rather cheap when compared to the industry. CPRX is cheaper than 96.81% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of CPRX to the average of the S&P500 Index (36.12), we can say CPRX is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.61 | ||
| Fwd PE | 13.6 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of CPRX indicates a rather cheap valuation: CPRX is cheaper than 98.12% of the companies listed in the same industry.
97.75% of the companies in the same industry are more expensive than CPRX, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 12.26 | ||
| EV/EBITDA | 7.38 |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
CPRX has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)1.01
PEG (5Y)0.4
EPS Next 2Y14.64%
EPS Next 3Y10.93%
5. Dividend
5.1 Amount
No dividends for CPRX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
23.41
-0.02 (-0.09%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners85.12%
Inst Owner Change1.43%
Ins Owners5.59%
Ins Owner Change1.61%
Market Cap2.88B
Revenue(TTM)578.20M
Net Income(TTM)217.63M
Analysts88.57
Price Target35.19 (50.32%)
Short Float %6.93%
Short Ratio5.47
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)14.08%
Min EPS beat(2)4.13%
Max EPS beat(2)24.03%
EPS beat(4)4
Avg EPS beat(4)21.33%
Min EPS beat(4)4.13%
Max EPS beat(4)29.76%
EPS beat(8)8
Avg EPS beat(8)18.46%
EPS beat(12)11
Avg EPS beat(12)14.56%
EPS beat(16)13
Avg EPS beat(16)9.74%
Revenue beat(2)2
Avg Revenue beat(2)4.27%
Min Revenue beat(2)2.19%
Max Revenue beat(2)6.34%
Revenue beat(4)4
Avg Revenue beat(4)4.39%
Min Revenue beat(4)2.19%
Max Revenue beat(4)6.34%
Revenue beat(8)7
Avg Revenue beat(8)3.51%
Revenue beat(12)11
Avg Revenue beat(12)3.34%
Revenue beat(16)13
Avg Revenue beat(16)2.97%
PT rev (1m)1.47%
PT rev (3m)1.47%
EPS NQ rev (1m)6.62%
EPS NQ rev (3m)9.43%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.14%
Revenue NQ rev (1m)3.08%
Revenue NQ rev (3m)3.47%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.19%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.61 | ||
| Fwd PE | 13.6 | ||
| P/S | 4.98 | ||
| P/FCF | 12.26 | ||
| P/OCF | 12.26 | ||
| P/B | 3.13 | ||
| P/tB | 3.63 | ||
| EV/EBITDA | 7.38 |
EPS(TTM)1.72
EY7.35%
EPS(NY)1.72
Fwd EY7.35%
FCF(TTM)1.91
FCFY8.16%
OCF(TTM)1.91
OCFY8.16%
SpS4.7
BVpS7.49
TBVpS6.44
PEG (NY)1.01
PEG (5Y)0.4
Graham Number17.02
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.69% | ||
| ROE | 23.65% | ||
| ROCE | 28.06% | ||
| ROIC | 21.23% | ||
| ROICexc | 84.1% | ||
| ROICexgc | 187.79% | ||
| OM | 44.78% | ||
| PM (TTM) | 37.64% | ||
| GM | 85.68% | ||
| FCFM | 40.59% |
ROA(3y)18.85%
ROA(5y)22.43%
ROE(3y)22.87%
ROE(5y)26.38%
ROIC(3y)20.37%
ROIC(5y)19.67%
ROICexc(3y)162.63%
ROICexc(5y)159.51%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)26.92%
ROCE(5y)25.99%
ROICexgc growth 3Y8.72%
ROICexgc growth 5YN/A
ROICexc growth 3Y-30.16%
ROICexc growth 5YN/A
OM growth 3Y2.16%
OM growth 5Y5%
PM growth 3Y5.91%
PM growth 5Y1.34%
GM growth 3Y0.61%
GM growth 5Y0.11%
F-Score6
Asset Turnover0.55
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 0.31% | ||
| Cap/Sales | 0.02% | ||
| Interest Coverage | 593.88 | ||
| Cash Conversion | 79.12% | ||
| Profit Quality | 107.83% | ||
| Current Ratio | 6.62 | ||
| Quick Ratio | 6.4 | ||
| Altman-Z | 15.94 |
F-Score6
WACC8.64%
ROIC/WACC2.46
Cap/Depr(3y)0.72%
Cap/Depr(5y)100.44%
Cap/Sales(3y)0.06%
Cap/Sales(5y)0.18%
Profit Quality(3y)162.12%
Profit Quality(5y)139.35%
High Growth Momentum
Growth
EPS 1Y (TTM)45.76%
EPS 3Y52.41%
EPS 5Y34.29%
EPS Q2Q%20%
EPS Next Y13.52%
EPS Next 2Y14.64%
EPS Next 3Y10.93%
EPS Next 5Y26.8%
Revenue 1Y (TTM)25.56%
Revenue growth 3Y51.72%
Revenue growth 5Y36.89%
Sales Q2Q%15.31%
Revenue Next Year16.1%
Revenue Next 2Y12.2%
Revenue Next 3Y11.06%
Revenue Next 5Y11.21%
EBIT growth 1Y48.97%
EBIT growth 3Y55%
EBIT growth 5Y43.74%
EBIT Next Year63.54%
EBIT Next 3Y23.99%
EBIT Next 5YN/A
FCF growth 1Y83.47%
FCF growth 3Y59.11%
FCF growth 5Y47.22%
OCF growth 1Y83.42%
OCF growth 3Y58.35%
OCF growth 5Y47.28%
CATALYST PHARMACEUTICALS INC / CPRX FAQ
What is the ChartMill fundamental rating of CATALYST PHARMACEUTICALS INC (CPRX) stock?
ChartMill assigns a fundamental rating of 8 / 10 to CPRX.
What is the valuation status of CATALYST PHARMACEUTICALS INC (CPRX) stock?
ChartMill assigns a valuation rating of 7 / 10 to CATALYST PHARMACEUTICALS INC (CPRX). This can be considered as Undervalued.
Can you provide the profitability details for CATALYST PHARMACEUTICALS INC?
CATALYST PHARMACEUTICALS INC (CPRX) has a profitability rating of 9 / 10.
What is the financial health of CATALYST PHARMACEUTICALS INC (CPRX) stock?
The financial health rating of CATALYST PHARMACEUTICALS INC (CPRX) is 8 / 10.